Flavia Borellini
Known title: DirectorCIK: 0001867426
Associated companies
Transaction History
| RVMD | ▲ Buy | Grant | 1,191 | $0 | 6/18/2026 | View on chart |
| RVMD | ▲ Buy | Grant | 3,142 | $0 | 6/26/2025 | View on chart |
| RVMD | ▲ Buy | Grant | 4,800 | $0 | 6/20/2024 | View on chart |
| RVMD | ▲ Buy | Grant | 5,200 | $0 | 6/8/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 5,200 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.